| Bjorn Batdorf, MD | |
|
3300 Oakdale Ave N, Robbinsdale, MN 55422-2926 | |
| (763) 520-5200 | |
| Not Available |
| Full Name | Bjorn Batdorf |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 14 Years |
| Location | 3300 Oakdale Ave N, Robbinsdale, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285954933 | NPI | - | NPPES |
| H400442792 | Other | MN | MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0101X | Pathology - Anatomic Pathology | 2017-00804 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Memorial Health | Robbinsdale, MN | Hospital |
| Maple Grove Hospital | Maple grove, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Memorial Health Care | 0042123028 | 483 |
News Archive
In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from The University of Texas MD Anderson Cancer Center determined the rate of additional breast biopsies needed for these patients during their follow-up care.
Antibodies combat viruses and bacteria. They also attach themselves to cancer cells - in a typical, characteristic way. Fraunhofer scientists are using this property to detect cancer cells in tissue samples. Such rapid tests can already be applied by surgeons during operations - within a few minutes and without expensive equipment.
Why do patients who receive antipsychotic medications to manage schizophrenia and bipolar disorder quickly gain weight and develop prediabetes and hyperinsulemia?
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine (Xeloda) as a treatment for advanced, metastatic colorectal cancer.
› Verified 4 days ago
| Entity Name | North Memorial Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851344907 PECOS PAC ID: 0042123028 Enrollment ID: O20040122000470 |
News Archive
In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from The University of Texas MD Anderson Cancer Center determined the rate of additional breast biopsies needed for these patients during their follow-up care.
Antibodies combat viruses and bacteria. They also attach themselves to cancer cells - in a typical, characteristic way. Fraunhofer scientists are using this property to detect cancer cells in tissue samples. Such rapid tests can already be applied by surgeons during operations - within a few minutes and without expensive equipment.
Why do patients who receive antipsychotic medications to manage schizophrenia and bipolar disorder quickly gain weight and develop prediabetes and hyperinsulemia?
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine (Xeloda) as a treatment for advanced, metastatic colorectal cancer.
› Verified 4 days ago
| Entity Name | North Pathology Associates Pllp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720048556 PECOS PAC ID: 0244383347 Enrollment ID: O20090807000215 |
News Archive
In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from The University of Texas MD Anderson Cancer Center determined the rate of additional breast biopsies needed for these patients during their follow-up care.
Antibodies combat viruses and bacteria. They also attach themselves to cancer cells - in a typical, characteristic way. Fraunhofer scientists are using this property to detect cancer cells in tissue samples. Such rapid tests can already be applied by surgeons during operations - within a few minutes and without expensive equipment.
Why do patients who receive antipsychotic medications to manage schizophrenia and bipolar disorder quickly gain weight and develop prediabetes and hyperinsulemia?
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine (Xeloda) as a treatment for advanced, metastatic colorectal cancer.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bjorn Batdorf, MD 101 Manning Dr, Chapel Hill, NC 27514-4220 Ph: (612) 624-8199 | Bjorn Batdorf, MD 3300 Oakdale Ave N, Robbinsdale, MN 55422-2926 Ph: (763) 520-5200 |
News Archive
In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from The University of Texas MD Anderson Cancer Center determined the rate of additional breast biopsies needed for these patients during their follow-up care.
Antibodies combat viruses and bacteria. They also attach themselves to cancer cells - in a typical, characteristic way. Fraunhofer scientists are using this property to detect cancer cells in tissue samples. Such rapid tests can already be applied by surgeons during operations - within a few minutes and without expensive equipment.
Why do patients who receive antipsychotic medications to manage schizophrenia and bipolar disorder quickly gain weight and develop prediabetes and hyperinsulemia?
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine (Xeloda) as a treatment for advanced, metastatic colorectal cancer.
› Verified 4 days ago
Dr. Daryl Ray Tharp Jr., MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5200 | |
Dr. Bradley A Brown, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-581-4131 | |
Katharine Van Patten, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Surgical Pathology Department, Robbinsdale, MN 55422 Phone: 763-581-4150 Fax: 763-581-4151 | |
Tarek A. Salem, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5200 |